Cancer Information Charity Foundation (CICF) announced on Oct. 25 the survey results on “Treatment of Brain Metastasis in Non-Small Cell Lung Cancer Patients.” The survey found that over 90 percent of the respondents understand that brain metastasis is common in lung cancer, and more than 80 percent of them believe it is necessary to understand the treatment methods for brain metastasis before starting treatment. The “Cancer Information Network” stated that new third-generation targeted therapies have emerged, which can more effectively control the symptoms of brain metastasis, and urged authorities to promptly include these drugs in the safety net provided by the Hospital Authority to benefit lung cancer patients.

The brain is a common site for metastasis lung cancer, especially in cases of Anaplastic Lymphoma Kinase (ALK) non-small cell lung cancer, where approximately 30-40 percent of patients may develop brain metastasis. In June and July of this year, CICF surveyed 100 non-small cell lung cancer patients. The results revealed that 93 percent of the respondents were aware of the frequent occurrence of brain metastasis in lung cancer, and it imposed significant emotional stress on patients. They considered the impact on the brain and their overall quality of life as their primary concerns. Eighty-three percent of the respondents believed that it is essential to understand the treatment methods for brain metastasis before initiating any treatment. When contemplating new therapies, the effectiveness of treating brain metastasis was deemed the most critical factor, followed by considerations of survival and symptom alleviation.

Posted in

Iron Will

Leave a Comment

You must be logged in to post a comment.